Prelude Therapeutics (PRLD) Net Equity Issued and Repurchased (2020 - 2021)

Prelude Therapeutics (PRLD) posted Net Equity Issued and Repurchased of $161.4 million for Q1 2021, up 384242.86% sequentially from $42000.0 in Q2 2020, and up 439.88% YoY from $29.9 million in Q1 2020.

Prelude Therapeutics (PRLD) Net Equity Issued and Repurchased (2020 - 2021) Analysis & Trends

Prelude Therapeutics has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $161.4 million in Q1 2021.

  • Quarterly Net Equity Issued and Repurchased rose 439.88% year-over-year to $161.4 million in Q1 2021, while the trailing twelve-month figure through Dec 2021 was $161.4 million (up 439.12% YoY) and the FY2021 annual result came in at $161.4 million, up 223.98% from the prior year.
  • Net Equity Issued and Repurchased grew to $161.4 million in Q1 2021 per PRLD's latest filing, from $42000.0 in the prior quarter.
  • Over five years, Net Equity Issued and Repurchased peaked at $161.4 million in Q1 2021 and troughed at $42000.0 in Q2 2020.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 141.90 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Prelude Therapeutics 442.91 Mn 162.28 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2021 161.42 Mn
Mar 31, 2021 161.42 Mn
Jun 30, 2020 42,000.00
Jun 30, 2020 42,000.00
Mar 31, 2020 29.90 Mn
Mar 31, 2020 29.90 Mn